CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Conference call webcast is scheduled for November 22 at 9 a.m. ET.

SINGAPORE, Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results and provided clinical and corporate updates.  

Read more at prnewswire.com